Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Celia Fontanillo

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Blood|June 29, 2026
NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple MyelomaBo Hu, Jacob Edwards, Hardik Modi, et al.
Blood Cancer Discovery|November 3, 2025
Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell LymphomaZhongying Mo, Lynda Groocock, Scott Wood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancerSurendra Nayak, John D Norris, Massimo Ammirante, et al.
Cell|November 24, 2014
A proteome-scale map of the human interactome networkThomas Rolland, Murat Taşan, Benoit Charloteaux, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Blood|June 29, 2026
NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple MyelomaBo Hu, Jacob Edwards, Hardik Modi, et al.
Blood Cancer Discovery|November 3, 2025
Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell LymphomaZhongying Mo, Lynda Groocock, Scott Wood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancerSurendra Nayak, John D Norris, Massimo Ammirante, et al.
Cell|November 24, 2014
A proteome-scale map of the human interactome networkThomas Rolland, Murat Taşan, Benoit Charloteaux, et al.
Pageof 3